Brought to you by 
GSK gets rights to Prosensa's PRO051, options on other molecules; terminated
11 Dec 2015
Executive Summary
Prosensa BV (antisense oligonucleotides that modify disease-causing genes) has licensed GlaxoSmithKline exclusive global rights to its lead candidate Phase I/II PRO051 for Duchenne muscular dystrophy (DMD), plus exclusive options on Phase I PRO044 and two other molecules once studies are completed. Each of these four therapeutics is for a different subpopulation of DMD. The alliance was established under GSK's Center of Excellence for External Drug Discovery (CEEDD).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK gets rights to Prosensa's PRO051, options on other molecules; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice